Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy

Shan Zhang†, Yaohui Wang†, Yan Wang, Jing Peng, Chenwei Yuan, Liheng Zhou, Shuguang Xu, Yanping Lin, Yueyao Du, Fan Yang, Jie Zhang, Huijuan Dai, Wenjin Yin* and Jinsong Lu*

Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Background: We aimed to explore whether the expression of serum miR-222-3p might contribute to early prediction of therapeutic response, clinical outcomes, and adverse events for HER2-positive breast cancer patients receiving neoadjuvant therapy (NAT).

Methods: A total of 65 HER2-positive breast cancer patients receiving NAT were analyzed. The concentration of serum miR-222-3p was detected by quantitative real-time PCR. Logistic regression analysis was used to identify the association of serum miR-222-3p with pathological complete response (pCR). The relationship of serum miR-222-3p with disease-free survival (DFS) and overall survival (OS) was examined via log-rank test and Cox proportional hazards analysis. The ordered logistic regression was applied to evaluate the association between serum miR-222-3p and adverse events.

Results: The miR-222-3p low group was more likely to achieve pCR \([\text{OR} = 0.258, P = 0.043]\). The interaction between miR-222-3p and presenting Ki67 level was also detected for pCR \([\text{OR} = 49.230, P_{\text{interaction}} = 0.025]\). The miR-222-3p low group was correlated with superior DFS \([P = 0.029]\) and OS \([P = 0.0037]\). The expression of serum miR-222-3p was the independent protective factor for trastuzumab-induced cardiotoxicity \([P < 0.05]\) and anemia \([P = 0.013]\).

Conclusions: Serum miR-222-3p is the potential factor to predict pCR, survival benefit and trastuzumab-induced cardiotoxicity for HER2-positive breast cancer patients receiving NAT.

Keywords: breast cancer, serum miR-222-3p, neoadjuvant therapy, predictive, prognostic, adverse event

INTRODUCTION

Neoadjuvant chemotherapy (NAC) is increasingly used in primary breast cancer patients, which not only aims to improve the operability or breast-conservability, but also serves as a good platform for \textit{in-vivo} tests of various drugs \((1–3)\). Trastuzumab, an anti-HER2 monoclonal antibody, is well exemplified in the treatment of HER2-positive breast cancer \((4)\). Manifold data have demonstrated...
that the addition of trastuzumab to NAC significantly improves the pathological complete response (pCR) rates and thereby results in survival benefit (5–8). However, a majority of HER2-positive breast cancer patients still failed to achieve pCR or even progressed despite trastuzumab-based neoadjuvant therapy (NAT) (9–12). Given the aggressive biological behavior of HER2-positive breast cancer, it hints at a demand to identify potential biomarkers to predict its response to NAT.

On the other hand, adverse events, especially trastuzumab-induced cardiotoxicity, also accompany during or after NAT. The overall incidence of cardiotoxicity was reportedly 3-7% for trastuzumab monotherapy, 13% for trastuzumab with paclitaxel, and as high as 27% for trastuzumab with anthracycline (13, 14). Unfortunately, few reliable biomarkers could help to predict the trastuzumab-induced cardiotoxicity.

Liquid biopsy, as a minimally invasive test, has developed dramatically in recent years. MicroRNAs (miRNAs) belong to a class of noncoding, regulatory, single-stranded RNAs, which have been reported to contribute in early detection of treatment efficacy and adverse reaction (15–23). Our previous research showed that the expression level of miR-222-3p in serum declined after surgery and was an independent prognostic factor for disease-free survival (DFS) in breast cancer (24). Basic studies revealed that miR-222-3p could upregulate HER2 signaling pathway in fulvestrant-resistant breast cancer cells and inhibit the autophagy of cardiac myocytes in mice (25–27). Previous studies have revealed that miR-222-3p was associated with immune invasion and immune resistance in a variety of tumors. Overexpression of miR-222-3p was found to enhance the resistance of tumor cells to tumor infiltrating lymphocytes (TILs) by down-regulating the expression of intercellular cell adhesion molecule-1 (ICAM1) in melanoma, which resulted in ipilimumab (anti-cytotoxic T lymphocyte-associated antigen-4 antibody) resistance in patients with melanoma (28). On the other hand, Ying et al. found that in epithelial ovarian cancer, cancer cell-derived exosomes with high contents of miR-222-3p transferred to the tumor-associated macrophages (TAM) and then induced their polarization to the M2 phenotype via SCOX3/STAT3 pathway (29). The transformation of TAM from M1 to M2 phenotype predicted poor prognosis (30) and contributed to the resistance to anti-HER2/Neu treatment in breast cancer (31). However, it still remains ill-defined whether serum miR-222-3p can serve as a potential biomarker for predicting the response to NAT in HER2-positive breast cancer patients as well as their trastuzumab-induced cardiotoxicity.

On these premises, we hypothesized that the expression of serum miR-222-3p might contribute to early prediction of therapeutic response, clinical outcomes and adverse events for HER2-positive breast cancer patients receiving NAT.

MATERIALS AND METHODS

Study Procedure
All the enrolled HER2-positive breast cancer patients came from two neoadjuvant clinical trials registered as SHPD001 (NCT02199418) and SHPD002 (NCT02221999) in ClinicalTrials.gov. The SHPD001 and SHPD002 trials were verified and authorized by the Independent Ethical Committee of Renji Hospital, Shanghai Jiaotong University. Each patient signed written informed consent.

The eligibility criteria for these two neoadjuvant trials included women aged ≥18 and ≤70 years old with locally advanced invasive breast cancer (T2-4 or N1-3) confirmed independently by two pathologists based on World Health Organization (WHO) classification. All the patients received paclitaxel 80 mg/m² on day 1, 8, 15 and 22 and cisplatin 25 mg/m² on day 1, 8 and 15 every 4 weeks for 4 cycles. For HER2-positive patients, concurrent weekly trastuzumab was given at a loading-dose of 4 mg/kg, followed by maintenance dose of 2.4 mg/kg, on day 1 for 16 weeks. However, 6 HER2-positive breast cancer patients couldn’t afford to receive trastuzumab. In the SHPD002 trial, hormone receptor (HR)-positive patients were randomly assigned to receive preoperative endocrine therapy or not. Endocrine therapy hereinto referred to gonadotropin releasing hormone agonist for premenopausal women and letrozole for postmenopausal counterparts, concurrently with NAC. Tumor assessment was performed every 2 months by physical examination, mammary magnetic resonance imaging (MRI) and ultrasonography. All the patients were required to measure the left ventricular ejection fraction (LVEF) at baseline and every 3 months thereafter. Adverse events were graded according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0. After completion of NAT, the patients underwent surgery. Up until April 2018, 65 HER2-positive breast cancer patients were available for this analysis from these two trials. The results were reported and the analysis was devised according to the Tumor Marker Prognostic Report Recommendation (REMARK) guidelines (32, 33).

Study Outcome
The primary outcome of SHPD001 and SHPD002 was pCR, which was defined as the absence of tumor in the breast tissues and auxiliary lymph nodes removed at the time of surgery (ypT0 ypN0). The secondary outcomes of SHPD001 and SHPD002 included DFS, overall survival (OS) and adverse events. DFS was defined as the time from surgery until first occurrence of locoregional relapse, contralateral breast cancer, distant metastasis, second primaries and death from any cause. OS was defined as the time from surgery until death from any cause.

Pathological Examination
Estrogen receptor (ER), progesterone receptor (PR), HER2 and ki67 were evaluated by immunohistochemistry (IHC) in paraffin-embedded tumor samples from core needle biopsy. ER or PR positive was defined as ≥10% of stained cells. HER2-positive was defined as immunohistochemistry (IHC) 3+ or fluorescence in-situ hybridization (FISH) amplified according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline at that time. Clinical or pathological stage for each patient was determined according to
the seventh edition of the American Joint Committee on Cancer staging (AJCC-7).

**Sample Collection**

Before NAT, 5 mL peripheral blood was collected in the coagulation-promoting tubes and let stand at 4°C for at least 1 h. Then it was centrifuged at 1,000 x g for 10 min at 4°C to spin down the blood cells. The supernatants were centrifuged at 12,000 x g for 10 min at 4°C to completely remove cellular components. Subsequently, the serum samples were divided into 300 µl/tube in RNA-free EP tubes and stored at −80°C until use.

**Extraction of Total RNA**

The mirVana PARIS kit (Ambion, Texas, United States) was used to isolate total RNA from 300 µl serum in each patient according to manufacturer's instructions. The extracted RNAs were immediately stored at −80°C until use.

**Quantitative Real-Time PCR**

cDNA was obtained by reverse transcription of total RNA using a TaqMan Reverse Transcription Kit (Ambion, Texas, United States). For quantitative real-time PCR, the miRNA-specific TaqMan Small RNA Assays (Ambion, Texas, United States) for miR-222-3p and cel-miR-39 (reference microRNA) were used as described by the manufacturer. The TaqMan primers used for hsa-miR-222-3p (RT002276) and cel-miR-39 (RT000200) were obtained from Applied Biosystems. Briefly, 100 ng of total RNA was reverse transcribed using primers specific to each miRNA target followed by real-time PCR on LightCycler® 480 II (Roche, Mannheim, Germany) using TaKaRa probe qPCR kit (RR390A, TaKaRa, Dalian, China) according to the manufacturer's instructions. The expression of miR-222-3p relative to cel-miR-39 was determined using $2^{-\Delta Ct}$ method. $\Delta Ct$ = mean value Ct (miR-222-3p)−mean value Ct (reference miR-39).

**Statistical Analysis**

For pCR and survival analysis, the patients were dichotomized into miR-222-3p high ($2^{-\Delta Ct} > 0.03$) or low ($2^{-\Delta Ct} \leq 0.03$). Chi-square test or Fisher's test was performed to evaluate the correlation of serum miR-222-3p with clinicopathological characteristics. Logistic regression analysis was used to identify the association of serum miR-222-3p with pCR. Interaction of serum miR-222-3p was also tested with presenting ER or PR status, presenting Ki67 level and the use of neoadjuvant trastuzumab for pCR. The relationship of serum miR-222-3p with DFS and OS was examined via log-rank test and Cox proportional hazards analysis.

For safety analysis, the patients were trichotomized into miR-222-3p low [$2^{-\Delta Ct} \leq 0.006$ (at the 25th percentile)], intermediate

## Table 1

| Characteristics | N (%) | P value |
|-----------------|-------|---------|
| **Age (years)** |       |         |
| ≤50             | 10 (41.67) | 16 (39.02) | 0.834 |
| >50             | 14 (58.33)  | 25 (60.98)  |         |
| **Menopausal status** |     |         |
| Premenopausal   | 10 (41.67)  | 15 (36.59)  | 0.684 |
| Postmenopausal  | 14 (58.33)  | 26 (63.41)  |         |
| **Presenting clinical T stage** |     |         |
| T1              | 2 (4.88)    | 0 (0.00)    | 0.402* |
| T2              | 7 (17.07)   | 7 (29.17)   |         |
| T3              | 20 (48.78)  | 8 (33.33)   |         |
| T4              | 12 (29.27)  | 9 (37.50)   |         |
| **Presenting clinical N stage** |     |         |
| N0              | 9 (21.95)   | 0 (0.00)    | 0.016* |
| N1              | 26 (63.41)  | 23 (95.83)  |         |
| N2              | 2 (4.88)    | 0 (0.00)    |         |
| N3              | 4 (9.76)    | 1 (4.17)    |         |
| **Presenting ER status** |     |         |
| Negative        | 23 (56.10)  | 14 (58.33)  | 0.861  |
| Positive        | 18 (43.90)  | 10 (41.67)  |         |
| **Presenting PR status** |     |         |
| Negative        | 18 (43.90)  | 9 (37.50)   | 0.613  |
| Positive        | 23 (56.10)  | 15 (62.50)  |         |
| **Presenting Ki67 level** |     |         |
| ≤40%            | 22 (53.66)  | 12 (50.00)  | 0.776  |
| >40%            | 19 (46.34)  | 12 (50.00)  |         |
| **pCR** |       |         |
| Yes             | 22 (53.66)  | 9 (37.50)   | 0.208  |
| No              | 19 (46.34)  | 15 (62.50)  |         |
| **DFS event** |       |         |
| Yes             | 3 (7.32)    | 6 (25.00)   | 0.066* |
| No              | 38 (92.68)  | 18 (75.00)  |         |
| **Death** |       |         |
| Yes             | 0 (0.00)    | 3 (12.50)   | 0.046* |
| No              | 41 (100.00) | 21 (87.50)  |         |

## Table 2

**Multivariate logistic analysis for predictive factors of pCR.**

| Characteristics | Multivariate logistic analysis |
|-----------------|-------------------------------|
| **pCR** |       |         |
| Yes             | 22 (53.66)  | 9 (37.50) | 0.208  |
| No              | 19 (46.34)  | 15 (62.50) |         |
| **DFS event** |       |         |
| Yes             | 3 (7.32)    | 6 (25.00) | 0.066* |
| No              | 38 (92.68)  | 18 (75.00) |         |
| **Death** |       |         |
| Yes             | 0 (0.00)    | 3 (12.50) | 0.046* |
| No              | 41 (100.00) | 21 (87.50) |         |

ER, estrogen receptor; PR, progesterone receptor; pCR, pathological complete response; DFS, disease-free survival.

*Fisher’s test.
(0.006 < $2^{-\Delta Ct} \leq 0.053$) or high [$2^{-\Delta Ct} > 0.053$ (at the 75th percentile)]. The ordered logistic regression was applied to evaluate the association between serum miR-222-3p and adverse events. The relative and absolute drop of LVEF from baseline were respectively calculated when the LVEF measured at two time points or more were available. The relative drop of LVEF from baseline (rLVEF) was defined as $(LVEF_{min} - LVEF_{baseline})/LVEF_{baseline}$, and the absolute drop of LVEF from baseline (aLVEF) as $LVEF_{min} - LVEF_{baseline}$. Since grade 3/4 LVEF decrease occurred in only a minority of patients, either rLVEF or aLVEF was divided by its quartile.

The statistical analysis was performed by STATA Statistics SE 14 (Stata Corp LP, College Station, TX, USA). All tests were two-tailed and $P < 0.05$ was considered statistically significant.

**RESULTS**

### The Association Between the Expression of Serum miR-222-3p and the Clinicopathological Characteristics

The baseline characteristics of all the patients are listed in Table 1. The expression of serum miR-222-3p was associated with presenting clinical N stage ($P = 0.016$) and death ($P = 0.046$). The miR-222-3p low group tended to experience less DFS events ($P = 0.066$). Significant correlation failed to be discovered between serum miR-222-3p and other clinicopathological characteristics.

### The Association Between the Expression of Serum miR-222-3p and the pCR Rate

In general, 31 out of 65 (47.69%) patients reached pCR. In the multivariate analysis, the miR-222-3p low group was more likely to achieve pCR [OR = 0.258, 95% confidence interval (CI): 0.070–0.958, $P = 0.043$]. Meanwhile, patients with lower ER expression (OR = 0.050, 95% CI: 0.007–0.347, $P = 0.002$) and higher Ki67 (OR = 7.155, 95% CI: 1.857–27.566, $P = 0.004$) were much easier to achieve pCR (Table 2). The interaction between miR-222-3p and presenting Ki67 level was also detected for pCR (OR = 49.230, 95% CI: 1.624–1492.078, $P_{interaction} = 0.025$; Figure 1). However, no interaction of miR-222-3p was found with presenting ER or PR status and the use of neoadjuvant trastuzumab.

### Survival Analysis

In either univariate ($P = 0.0273$; Figure 2) or multivariate [hazard ratio (HR) = 5.778, 95% CI: 1.196–27.906, $P = 0.029$; Table 3] survival analysis, superior DFS was seen in the miR-222-3p low group. Furthermore, the lower expression of serum miR-222-3p was also related with better OS ($P = 0.0037$; Figure 3).

### The Association Between the Expression of Serum miR-222-3p and Adverse Events

The ordered logistic regression analysis showed that the expression of serum miR-222-3p was the independent protective factor for rLVEF (OR = 0.410, 95% CI: 0.175–0.962, $P = 0.040$; Table 4), aLVEF (OR = 0.394, 95% CI: 0.166–0.937, $P = 0.035$; Table 4), and anemia (OR = 0.408, 95% CI: 0.201–0.828, $P = 0.013$; Table 4). Alopecia (OR = 1.935, 95% CI: 0.893–4.193, $P = 0.094$) and constipation (OR = 2.234, 95% CI: 0.940–5.308, $P = 0.069$) were marginally correlated with the expression of serum miR-222-3p (Table 4).

### DISCUSSION

This study, to the best of our knowledge, is the first to report the association between the expression of serum miR-222-3p and the response to NAT in the HER2-positive breast cancer patients. This is also the first time to report the relationship between the serum miR-222-3p expression level and adverse events.
Serum miRNAs were identified as biomarkers to diagnose or predict prognosis in various carcinomas (34, 35). Some basic studies demonstrated that tumor can release miRNAs into circulation and serum miRNAs exist in a remarkably stable form protected from endogenous RNase activity (36, 37), while others indicated the presence of miRNA-enriched exosomes secreted by non-cancer cells such as adipose tissue macrophages and mesenchymal stromal cells (38–40). Therefore, certain miRNAs, with cancer-specific functions, might produce endocrine, paracrine or autocrine effect (41–44) on breast cancer patients, directly or indirectly regulating their response to NAT.

Our data reveal that higher level of serum miR-222-3p was associated with inferior pCR rate, which might be attributed to trastuzumab-resistance. So far, two important pathways might contribute to trastuzumab resistance. Firstly, the activation of phosphatase and tension homologs (PTEN) predicts inhibitory effect of trastuzumab, whereas PI3K pathway activation through PTEN loss and PIK3CA mutation confers trastuzumab resistance in breast cancer (45–49). Secondly, PTEN loss leads to SRC hyperactivation, and SRC inhibition appears to overcome trastuzumab resistance (50–53). On the other hand, miR-222 was reported to promote adriamycin or tamoxifen resistance through PTEN/Akt pathway in breast cancer (54, 55). Consequently, miR-222-3p may also induce trastuzumab resistance by modulating the PTEN/PI3K/Akt pathway and the expression of SRC, which prompts further investigation.

We observed the poor prognosis in the patients with higher level of serum miR-222-3p. An increasing number of researches have demonstrated that miR-222 promotes epithelial-to-mesenchymal transition (EMT) (26, 56, 57), G1/S transition of cell cycle (58) and cell proliferation (59, 60) in breast cancer. Therefore, the expression level of miR-222-3p is responsible for the invasion and metastasis of breast cancer. The prognostic value of miR-222 has also been clarified not only in breast cancer (24, 61) but also in many other malignancies including pancreatic cancer, bladder cancer and glioblastoma (62–66). Furthermore, the anti-miR-222 might improve the chemosensitivity and survival, which provides a novel strategy for breast cancer management (67).

Trastuzumab administration is associated with an increased risk of cardiovascular adverse events (68–70). However, the underlying mechanism remains suspended. Trastuzumab-induced cardiotoxicity, regarded as a type II adverse drug reaction, commonly cause reversible dysfunction without cell loss (71). It generally presents as asymptomatic LVEF decline (72–74). Moreover, LVEF decline frequently improves with drug interruption and resuming trastuzumab after recovery is often feasible (71, 74). This study showed that the impairment of LVEF was associated with the expression level of serum miR-222-3p in this study. MiR-222 has been found to participate

### TABLE 3 | Multivariate survival analysis of serum miR-222-3p and DFS.

| Characteristics              | HR    | 95% CI     | P value |
|------------------------------|-------|------------|---------|
| MIR-222-3p (high vs. low)    | 5.778 | 1.196–27.906 | 0.029   |
| T stage (T3-4 vs. T1-2)      | 1.172 | 0.274–5.019  | 0.831   |
| N stage (N2-3 vs. N0-1)      | 2.580 | 0.259–25.736 | 0.419   |
| ER (positive vs negative)    | 2.318 | 0.336–15.969 | 0.393   |
| PR (positive vs negative)    | 0.730 | 0.097–5.474  | 0.759   |
| Ki67 (>40% vs. ≤40%)         | 0.791 | 0.202–3.098  | 0.738   |

DFS: disease-free survival; ER, estrogen receptor; PR, progesterone receptor; HR, hazard ratio; CI, confidence interval.

### TABLE 4 | The association of serum miR-222-3p and adverse events.

| Adverse event                  | Serum miR-222-3p |
|-------------------------------|-----------------|
|                               | N   | OR     | 95% CI     | P  |
| rLVEF                         | 36  | 0.410  | 0.175–0.962 | 0.040 |
| aLVEF                         | 36  | 0.394  | 0.166–0.937 | 0.035 |
| ALT increase                  | 59  | 1.340  | 0.566–3.465 | 0.467 |
| AST increase                  | 59  | 0.938  | 0.452–1.948 | 0.865 |
| ALP increase                  | 59  | 1.072  | 0.148–7.750 | 0.945 |
| Blood bilirubin increase      | 59  | 1.177  | 0.591–2.342 | 0.643 |
| Creatinine increase           | 59  | 0.820  | 0.383–1.757 | 0.610 |
| Leukemia                      | 59  | 0.852  | 0.439–1.653 | 0.635 |
| Neutropenia                   | 59  | 0.675  | 0.350–1.230 | 0.240 |
| Thrombocytopenia              | 59  | 1.072  | 0.148–7.750 | 0.945 |
| Anemia                        | 59  | 0.406  | 0.201–0.828 | 0.013 |
| Peripheral neuropathy         | 59  | 0.938  | 0.477–1.843 | 0.852 |
| Nausea                        | 59  | 1.486  | 0.729–3.040 | 0.276 |
| Vomiting                      | 59  | 1.161  | 0.551–2.448 | 0.694 |
| Alopecia                      | 59  | 1.935  | 0.890–4.193 | 0.094 |
| Constipation                  | 59  | 2.234  | 0.940–5.308 | 0.069 |
| Diarrhea                      | 59  | 1.024  | 0.523–2.005 | 0.944 |
| Fatigue                       | 59  | 0.761  | 0.368–1.572 | 0.460 |

OR, odds ratio; CI, confidence interval; rLVEF, relative drop of left ventricular ejection fraction from baseline; aLVEF, absolute drop of left ventricular ejection fraction from baseline; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase.
in many physiological and pathological processes in the cardiovascular system (75). Additionally, miR-222 is necessary for cardiomyocyte growth induced by exercise and is sufficient to protect against adverse cardiac remodeling after ischemic injury (76, 77). Serum miR-222-3p may play an endocrine role similar to that of hormones, reaching every organ, tissue or cell in the body with blood circulation. When miR-222-3p acts on cancer cells, it plays a role in carcinogenesis and drug resistance, and when it acts on cardiac myocytes, it plays a role in protecting the heart. Therefore, the overexpression of miR-222-3p might prevent the heart from trastuzumab-induced injury.

As far as we know, this is the first time that patients with lower expression level of serum miR-222-3p have been reported prone to anemia after receiving NAT. However, the molecular mechanism has not been clarified. The progressively down-regulating of miR-222-3p was observed during the normal erythropoiesis (78). In addition, miR-222-3p inhibited the expansion of erythroblasts and hematopoietic differentiation via down-regulated c-kit expression and miR-222-3p decreased the expression of BLVRA and CRKL to suppress erythroid differentiation (79–81). Consistent with previous basic studies, our data also showed that the patients with high miR-222-3p level have lower baseline hemoglobin level (OR = 0.07, 95% CI 0.005–0.991, P = 0.049). These results suggested that the erythroblasts may be more resistant to chemotherapy in the high miR-222-3p group due to the lower proliferative activity and conversely patients with low level of miR-222-3p might be prone to anemia.

The limitations of this study were as follows. Firstly, the sample size was relatively small. Large-scale studies are needed to confirm the predictive and prognostic value of miR-222-3p. Secondly, some follow-up data are missing on adverse events. Thirdly, as the serum samples were collected before NAT in this retrospective study of prospective trials, it was not possible for us to evaluate the correlation of miR-222-3p changes at different time points during or after NAT with various outcomes including response, survival and safety, which warrants further research.

In conclusion, our study revealed that serum miR-222-3p is the potential factor to predict pCR, survival benefit and trastuzumab-induced cardiotoxicity for HER2-positive breast cancer patients receiving NAT. However, the logic behind it is still open to investigation.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Independent Ethical Committee of Renji Hospital, Shanghai Jiaotong University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

SZ, YaoW, JL, and WY contributed conception and design of the study. SZ organized the database. YanW, JP, CY, LZ, SX, YL, YD, FY, JZ, and HD contributed acquisition of the data. SZ, YaoW, and WY performed the statistical analysis. SZ and YaoW wrote the first draft of the manuscript. WY and JL revised the manuscript. All authors read and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China [81172505, 81302302], the Doctoral Programs Foundation of the Ministry of Education of China [20120071120105], the Shanghai Natural Science Foundation [13ZR1452800], the Shanghai Municipal Commission of Health and Family Planning [2014Y0218, 201640006], the Clinical Research Plan of Shanghai Hospital Development Center [16CR3065B, 12016231], the Shanghai Rising Stars of Medical Talent Youth Development Program for Outstanding Youth Medical Talents [2018-16], the Shanghai Rising Stars of Medical Talent Youth Development Program for Youth Medical Talents—Specialist [2018-15], the Shanghai Collaborative Innovation Center for Translational Medicine [TM201908], the Shanghai Natural Science Foundation [19ZR1431100], the Multidisciplinary Cross Research Foundation of Shanghai Jiao Tong University [ZH2018QN42] and the Nurturing Fund of Renji Hospital [PY2018-IIC-01, PY2018-III-15].

REFERENCES

1. Colomer R, Saura C, Sanchez-Rovira P, Pascual T, Rubio IT, Burgues O, et al. Neoadjuvant management of early breast cancer: a Clinical and investigational position statement. Oncologist. (2019) 24:603–11. doi: 10.1634/theoncologist.2018-0228
2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. (2018) 19:27–39. doi: 10.1016/s1470-2045(17)30777-5
3. King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. (2015) 12:335–45. doi: 10.1038/nrclinonc.2015.63
4. Prat A, Pascual T, De Angelis G, Gutierrez C, Llombart-Cussac A, Wang T, et al. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. J Natl Cancer Inst. (2019) 112:46–54. doi: 10.1093/jnci/djyz042
5. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. (2014) 15:640–7. doi: 10.1016/s1470-2045(14)70080-4
6. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the nNOAH trial): a randomised
controlled superiority trial with a parallel HER2-negative cohort. Lancet. (2010) 375:377–84. doi: 10.1016/s0140-6736(09)61964-4

7. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. (2007) 13:228–33. doi: 10.1158/1078-0432.ccr-06-1345

8. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. (2005) 23:3676–85. doi: 10.1200/jco.2005.07.032

9. Fumagalli D, Venet D, Ignatidou M, Azim HA, Jr., Maetens M, et al. RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: A Secondary analysis of the neoALTO randomized clinical trial. JAMA Oncol. (2017) 3:227–34. doi: 10.1001/jamaoncol.2016.3824

10. Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, et al. Integrated analysis of rNA and dNA from the phase iII trial cALGB (2017) 3:227–34. doi: 10.1001/jamaoncol.2016.3824

11. Qin X, Guo H, Wang X, Zhu X, Yan M, Wang X, et al. Exosomal miR-196a determines chemoresistance by reprogramming metabolism in breast cancer. Cell Physiol Biochem. (2019) 35:1302–8. doi: 10.1007/s00978-019-14133-1

12. Zhang et al. miR-222-3p Predicting Efficacy and Cardiotoxicity of Breast Cancer Treatment (REMARK). J Natl Canc Inst. (2001) 93:10961–4. doi: 10.1093/jnci/93.21.10961

13. Xu M, Liu M, Du X, Li S, Li H, Li X, et al. Intratumoral delivery of anti-HER2/Neu siRNA induces head and neck cancer through targeting cDKN1B and iNG5. Drug Resist Updat. (2015) 18:142–50. doi: 10.1016/j.drup.2015.11.002

14. Leonetti A, Assaraf YG, Veltisda P, El Hassouni B, Tiseo M, Giovannetti E. MicroRNAs as a drug resistance mechanism to targeted therapies in eGFR-mutated NSCLC: current implications and future directions. Drug Resist Updat. (2019) 42:1–1. doi: 10.1016/j.drup.2018.11.002

15. Song H, Li X, Zhao Z, Qian J, Wang Y, Cui J, et al. Reversal of osteoporotic activity by endothelial cell-Secreted bone targeting and biocompatible exosomes. Nano Lett. (2019) 19:3040–8. doi: 10.1021/acs.nanolett.9b00287

16. Ying W, Rieopol M, Bandopadhyay G, Dong Y, Bongiam, Aseo B, et al. Adipose tissue macrophage-Derived exosomal miRNAs can modulate insulin sensitivity by endothelial cell-Derived exosomes acting through PPARγ signalling. Cell. (2017) 171:572–84.e12. doi: 10.1016/j.cell.2017.08.035

17. Zhang et al. miR-222-3p Predicting Efficacy and Cardiotoxicity of Breast Cancer Treatment (REMARK). J Natl Canc Inst. (2001) 93:10961–4. doi: 10.1093/jnci/93.21.10961

18. Thakral S,Ghoshal K. miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. J Natl Canc Inst. (2017) 109:1180–4. doi: 10.1093/jncl/dij237

19. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport rNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. (2008) 10:1470–6. doi: 10.1038/ncllb13000

20. Mitchell PS, Parkin RK, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. (2008) 105:10513–8. doi: 10.1073/pnas.080459105

21. Song H, Li X, Zhao Z, Qian J, Wang Y, Cui J, et al. Reversal of osteoporotic activity by endothelial cell-Secreted bone targeting and biocompatible exosomes. Nano Lett. (2019) 19:3040–8. doi: 10.1021/acs.nanolett.9b00287

22. Chaudhari U, Nemeth H, Gaspar JA, Hesscheler J, Hengstler JG,Sachindis A. MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. (2016) 90:3087–98. doi: 10.1007/s00204-016-1666-0

23. Amstutz U, Offer SM, Sistonen J, Joergner M, Diesso RB,Largent CR, Polymorphisms in miR27A associated with early-Onset toxicity in fluoropyrimidine-based chemotherapy. Clin Cancer Res. (2015) 21:2038–44. doi: 10.1158/1078-0432.ccr-14-2817
through miR-182-Regulated macrophage polarization. *Cardiovasc. Res.* (2019) 115:1205–16. doi: 10.1093/cvr/cvz040

51. Pakravan K, Babashah S, Sadeghzadeh M, Mowja SL, Mossaheb-Hoomahmedi M, Aetai F, et al. MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the miR-17/100/200c/FHIT-1α/VEGF signaling axis in breast cancer cells. *Cell Oncol. (Dordr).* (2017) 40:457–70. doi: 10.1007/s13402-017-0335-7

52. Thomou T, Mori MA, Dreyfuss JM, Konishi M, Sakaguchi M, Wolfrum C, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. *Nature.* (2017) 542:450–5. doi: 10.1038/nature21365

53. Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. *Hepatology.* (2012) 56:1946–57. doi: 10.1002/hep.25873

54. Deng Z, Yong Y, Teng Y, Zhang X, Samykutty A, Mu J, et al. Exosomes miR-126a released from mDSC induced by DOX treatment promotes lung metastasis. *Onco gene.* (2017) 36:639–51. doi: 10.1038/onc.2016.229

55. Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, et al. MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the miR-17/100/200c/FHIT-1α/VEGF signaling axis in breast cancer cells. *Cell Oncol. (Dordr).* (2017) 40:457–70. doi: 10.1007/s13402-017-0335-7

56. Li Y, Chu J, Feng W, Yang M, Zhang Y, Zhang Y, et al. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating stem cell-like properties. *Faseb J.* (2019) 33:4851–65. doi: 10.1096/fj.201701561RRR

57. Han S, Meng Y, Tong Q, Li G, Zhang X, Chen Y, et al. The ERBB2-targeting lncRNA gAS5 confers tamoxifen resistance by activating miR-222 in breast cancer. *Int J Oncol.* (2010) 37:1621–6. doi: 10.3892/ijo.0000886

58. Li Y, Liang C, Bo H, Zhao Q, Lu Y, Xiang Z, et al. miR-221-222 promotes s-phase entry and cellular migration in control of basal-like breast cancer. *Molecules.* (2014) 19:7122–37. doi: 10.3390/molecules19061272

59. Zhang C, Zhang J, Zhang A, Wang Y, Han L, You Y, et al. PUMA is a novel target of miR-221/222 in human epithelial cancers. *Int J Oncol.* (2010) 37:1621–6. doi: 10.3892/ijo.0000886

60. Zong Y, Zhang Y, Sun X, Xu T, Cheng X, Qin Y. miR-221-222 promote tumor growth and suppress apoptosis by targeting IncRNA gAS5 in breast cancer. *Biosci. Rep.* (2019) 39:1. doi: 10.1042/bsr20181589

61. Kim C, Ge EL. Kim A. Recurrence prediction using microRNA expression in hormone receptor positive breast cancer during taxofoxin treatment. *Biomarkers.* (2018) 23:804–11. doi: 10.1080/13545570.2018.1499131

62. Zhang Z, Pan B, Lv S, Ji Z, Wu Q, Lang R, et al. Integrating microRNA expression profiling studies to systematically evaluate the diagnostic value of microRNAs in pancreatic cancer and validate their prognostic significance with the cancer genome atlas data. *Cell Physiol Biochem.* (2018) 49:678–95. doi: 10.1159/000493033

63. Tisikrik FA, Averis M, Levens PK, Tokas T, Stravodimos K. Scorilas A. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients’ risk for short-term relapse and progression. *Genes Chrom Cancer.* (2018) 57:150–61. doi: 10.1002/gcc.22516

64. Zhao H, Shen J, Hodges TR, Song R, Fuller GN,Heimberger AB. Serum microRNA profiling in patients with glioblastoma: a survival analysis. *Mol. Cancer.* (2017) 16:59. doi: 10.1186/s12943-017-0682-5

65. Zhang L, Huang Z, Zhang H, Zhu M, Zhu W, Zhou X. et al. Prognostic value of candidate microRNAs in gastric cancer: a validation study. *Cancer Biomark.* (2017) 18:221–30. doi: 10.3233/cbm-160091

66. Zheng Z, Li X, Zhu Y, Wu X, Xie X, Jiang J. Prognostic significance of miRNA in patients with diffuse large b-Cell lymphoma: a meta-analysis. *Cell Physiol Biochem.* (2016) 39:1891–904. doi: 10.1159/000447887

67. Bliss SA, Sinha G, Sandiford OA, Williams LM, Engberdtt DJ, Guirko, et al. Mesenchymal stem cell Derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. *Cancer Res.* (2016) 76:5832–44. doi: 10.1158/0008-5472.can-16-1092

68. Bowles EI, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. *J Natl Cancer Inst.* (2012) 104:1293–305. doi: 10.1093/nci/djs317

69. Chen J, Long JB, Hurria A, Ouwosu C, Steinart RM,Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. *J Am Coll Cardiol.* (2012) 60:2504–12. doi: 10.1016/j.jacc.2012.07.068

70. Rochette L, Guenancia C, Gudjoncik A, Hachet O, Zeller M, Cotton Y, et al. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. *Trends Pharmacol Sci.* (2015) 36:326–48. doi: 10.1016/j.tips.2015.03.005

71. Zagar TM, Cardinale DM, Marks LB. Breast cancer therapy-associated cardiovascular disease. *Nat Rev Clin Oncol.* (2016) 13:172–84. doi: 10.1038/nrclinonc.2015.171

72. Portera CC, Walshe JM, Rosing DR, Destuluri N, Berman AW, Vatas U, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. *Clin Cancer Res.* (2008) 14:2710–6. doi: 10.1158/1078-0432.ccr-07-4636

73. Deng C, Guo H, Naita J, Yardley D, Marcom K, Albain K, et al. Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-Negative, ERBB2-Positive breast cancer. *JAMA Oncol.* (2016) 2:29–36. doi: 10.1001/jamaoncol.2015.3709

74. Barroso-Sousa R, Santana IA, Testa L, de Melo Gagliato D, Mano MS. Biological therapies in breast cancer: common toxicities and management strategies. *Breast.* (2013) 22:1009–18. doi: 10.1016/j.breast.2013.09.009

75. Ding S, Huang H, Yu X, Zhu H, Zheng C. miR-222 in cardiovascular diseases, physiology and pathology. *Biomol Res Int.* (2017) 2017:4962426. doi: 10.1155/2017/4962426

76. Vujic A, Lerchenmuller C, Wu TD, Guillermier C, Rabolli CP, Gonzalez E, et al. Exercise induces new cardiomyocyte generation in the adult mammalian heart. *Nat Commun.* (2018) 9:1659. doi: 10.1038/s41467-018-04083-1
77. Liu X, Xiao J, Zhu H, Wei X, Platt C, Damilano F, et al. miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. *Cell Metab.* (2015) 21:584–95. doi: 10.1016/j.cmet.2015.02.014

78. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. *Exp Hematol.* (2007) 35:1657–67. doi: 10.1016/j.exphem.2007.08.021

79. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. *Proc Natl Acad Sci USA.* (2005) 102:18081–6. doi: 10.1073/pnas.0506216102

80. Lee JY, Kim M, Heo HR, Ha KS, Han ET, Park WS, et al. Inhibition of microRNA-221 and 222 enhances hematopoietic differentiation from human pluripotent stem cells via c-KIT upregulation. *Mol Cells.* (2018) 41:971–8. doi: 10.14348/molcells.2018.0244

81. Jiang L, Wang X, Wang Y, Chen X. Quantitative proteomics reveals that miR-222 inhibits erythroid differentiation by targeting bLVRA and cRKL. *Cell Biochem Funct.* (2018) 36:95–105. doi: 10.1002/cbf.3321

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Zhang, Wang, Peng, Yuan, Zhou, Xu, Lin, Du, Yang, Zhang, Dai, Yin and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*